Abstract
Is it time for medical insurance companies to organize and fund clinical research that evaluates the role of new treatments (drugs or device-based therapies) in the context of existing clinical paradigms for common diseases?.
Original language | English (US) |
---|---|
Pages (from-to) | 685-689 |
Number of pages | 5 |
Journal | International Forum of Allergy and Rhinology |
Volume | 12 |
Issue number | 5 |
DOIs | |
State | Published - May 2022 |
Keywords
- biologics
- chronic rhinosinusitis with nasal polyps
- clinical research
- insurance
ASJC Scopus subject areas
- Immunology and Allergy
- Otorhinolaryngology